Results 171 to 180 of about 479,258 (314)
The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient-as-Own-Control Designs. [PDF]
Summar ML, Woodcock J.
europepmc +1 more source
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava +8 more
wiley +1 more source
The placebo effect shortens movement time in goal-directed movements. [PDF]
Fiorio M +3 more
europepmc +1 more source
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora +5 more
wiley +1 more source
Editorial: Placebo and Nocebo Effects in Psychiatry and Beyond
Katja Weimer +8 more
doaj +1 more source
The Placebo Effect in Medicine and Clinical Practice: A Narrative Review. [PDF]
Tzigkounakis G, Simati K, Georgiadis K.
europepmc +1 more source
MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. [PDF]
Nedrud MA +11 more
europepmc +1 more source
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie +12 more
wiley +1 more source
Placebo effect on brainstem activity associated with capsaicin-evoked urge to cough in healthy humans. [PDF]
Moe AAK +4 more
europepmc +1 more source
A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis
Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun +13 more
wiley +1 more source

